Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
Excellent. This is a crisis that defines a company and its leadership. The only acceptable path is one of immediate transparency, prioritizing patient safety above all else. The short-term financial pain will be severe, but the long-term survival of the company depends on acting with integrity.Read the full answer
As CEO, my primary fiduciary and ethical duty is to patients, regulators, and long-term shareholder value. The "6-month reporting timeline" cited by legal is almost certainly a misunderstanding of regulatory processes (likely conflating initial adverse event reporting with full label amendment review).Read the full answer